Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala… Read more
Cyclacel Pharmaceuticals Inc - Asset Resilience Ratio
Cyclacel Pharmaceuticals Inc (CYCC) has an Asset Resilience Ratio of -55.36% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2018)
This chart shows how Cyclacel Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Cyclacel Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $-2.98 Million | -55.36% |
| Total Liquid Assets | $-2.98 Million | -55.36% |
Asset Resilience Insights
- Limited Liquidity: Cyclacel Pharmaceuticals Inc maintains only -55.36% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Cyclacel Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Cyclacel Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Cyclacel Pharmaceuticals Inc (2003–2018)
The table below shows the annual Asset Resilience Ratio data for Cyclacel Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.33% | $66.00K | $19.82 Million | -0.17pp |
| 2017-12-31 | 0.51% | $132.00K | $26.00 Million | -0.16pp |
| 2016-12-31 | 0.67% | $132.00K | $19.66 Million | +0.14pp |
| 2015-12-31 | 0.53% | $132.00K | $24.76 Million | +0.08pp |
| 2014-12-31 | 0.45% | $132.00K | $29.39 Million | +0.08pp |
| 2013-12-31 | 0.37% | $132.00K | $35.52 Million | -0.42pp |
| 2012-12-31 | 0.79% | $153.00K | $19.35 Million | -75.73pp |
| 2011-12-31 | 76.52% | $19.89 Million | $26.00 Million | -15.87pp |
| 2010-12-31 | 92.39% | $29.07 Million | $31.46 Million | +87.54pp |
| 2008-12-31 | 4.85% | $1.50 Million | $30.96 Million | -31.72pp |
| 2007-12-31 | 36.58% | $27.77 Million | $75.91 Million | +21.15pp |
| 2006-12-31 | 15.43% | $9.76 Million | $63.28 Million | -34.42pp |
| 2005-12-31 | 49.85% | $10.69 Million | $21.45 Million | -10.26pp |
| 2004-12-31 | 60.11% | $33.42 Million | $55.60 Million | -0.98pp |
| 2003-12-31 | 61.08% | $11.30 Million | $18.50 Million | -- |